Children's Hospital of Philadelphia
Payal Jain is a research scientist responsible for basic and translational research to identify targeted therapeutics for treating pediatric low-grade gliomas (PLGG), with a focus on elucidating molecular mechanisms of response to therapy and subsequent resistance. She also seeks to understand the oncogenic role of both gene fusion partners in distinct PLGG gene fusions, focusing on a mechanistic understanding that would eventually lead to testing novel therapeutics, including small molecule inhibitors and subsequent resistance in PLGG patients. Payal uses relevant in vitro assays, cellular model systems and in vivo mouse preclinical models to answer scientific questions. She is also involved in writing scientific manuscripts and building a standard workflow to streamline our research efforts into a high-throughput process utilizing large-scale sequencing data generated by the D³b center.
Payal joined CHOP in August of 2016. She earned a B.Tech in Biotechnology from Amity University in India before completing a MA in Biotechnology from Columbia University in New York, NY. Payal completed a PhD in Biomedical Sciences at the University of Pennsylvania.
Children’s Hospital of Philadelphia
Genomic Landscape of Mixed Glial Neuronal Tumors
Mixed Neuronal-Glial Tumors (MNGT) are a benign category of tumor associated with seizures. Using the Pediatric Brain Tumor Atlas, researchers will analyze MNGT in hopes of guiding the development of treatments and predictive assessments.
Lea F. Surrey
MET Alterations in DMGs
Recent work has pointed to dysregulation of a cellular process called the mesenchymal-epithelial transition (MET) as a driver for diffuse midline gliomas (DMGs). This project will further explore this dysregulation in an effort to identify new therapeutic targets for DMGs.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with
Clinical Cancer Research
Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003
PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Cassie Kline, Payal Jain, Lindsay Kilburn, Erin R. Bonner, Nalin Gupta, John R. Crawford, Anu Banerjee, Roger J. Packer; Javier Villanueva-Meyer, Tracy Luks, Yalan Zhang, Madhuri Kambhampati, Jie Zhang, Sridevi Yadavilli, Bo Zhang, Krutika S. Gaonkar, Jo Lynne Rokita, Adam Kraya, John Kuhn, Winnie Liang; Sara Byron, Michael Berens, Annette Molinaro, Michael Prados, Adam Resnick, Sebastian M. Waszak, Javad Nazarian, Sabine Mueller
Pediatric Blood & Cancer
BRAF Fusions in Pediatric Histiocytic Neoplasms Define Distinct Therapeutic Responsiveness to RAF Paradox Breakers
Pediatric histiocytic neoplasms are hematopoietic disorders frequently driven by the BRAF‐V600E mutation. Here, we identified two BRAF gene fusions (novel MTAP‐BRAF and MS4A6A‐BRAF) in two aggressive histiocytic neoplasms. In contrast to previously described BRAF fusions, MTAP‐BRAF and MS4A6A‐BRAF d
Payal Jain Lea F. Surrey Joshua Straka Pierre Russo Richard Womer Marilyn M. Li Phillip B. Storm Angela J. Waanders Michael D. Hogarty Adam C. Resnick Jennifer Picarsic
Human Gene Therapy
Purification of mRNA Encoding Chimeric Antigen Receptor is Critical for Generation of Robust T-Cell Response
T cells made with messenger RNA (mRNA) encoding chimeric antigen receptor (CAR) offer a safe alternative to those transduced with viral CARs by mitigating the side effects of constitutively active T cells. Previous studies have shown that mRNA CAR T cells are transiently effective but lack persisten
Jessica B Foster, Namrata Choudhari, Jessica Perazzelli, Julie Storm, Ted J Hofmann, Payal Jain, Phillip Storm, Norbert Pardi, Drew Weissman, Angela J Waanders, Stephan A Grupp, Katalin Karikó, Adam C Resnick, PhD, David M Barrett